Blarcamesine - Anavex Life Sciences
Alternative Names: AE-37 hydrochloride; ANA001-HCl; ANAVEX; ANAVEX 2-73; Blarcamesine hydrochlorideLatest Information Update: 14 Feb 2024
At a glance
- Originator Anavex Life Sciences
- Developer Anavex Life Sciences; The Michael J. Fox Foundation for Parkinsons Research
- Class Antidementias; Antidepressants; Antiepileptic drugs; Antiparkinsonians; Anxiolytics; Behavioural disorder therapies; Dimethylamines; Furans; Neuroprotectants; Neuropsychotherapeutics; Nootropics; Small molecules
- Mechanism of Action Muscarinic receptor modulators; Sigma-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Alzheimer's disease
- Phase III Parkinson's disease
- Phase II/III Fragile X syndrome; Rett syndrome; Unspecified
- No development reported Angelman syndrome; Epilepsy
Most Recent Events
- 07 Feb 2024 Anavex Life Sciences plans a phase II trial for Schizophrenia in Q2 2024 (PO)
- 08 Jan 2024 Anavex Life Sciences has patent protection for Blarcamesine in Neurologic indications in USA
- 02 Jan 2024 Efficacy and adverse events data from a phase II/III trial in Rett Syndrome released by Anavex Life Sciences